{"podcast":{"title":"Business Of Biotech","slug":"business-of-biotech-123501","podcast_index_feed_id":123501,"rss_url":"https://rss.buzzsprout.com/1011661.rss","website_url":"https://www.bioprocessonline.com/solution/the-business-of-biotech-podcast","image_url":"https://storage.buzzsprout.com/35u0bccu9j9xpr9zrrjias54otax?.jpg","author":"Ben Comer","episode_count":310,"summary":"The Business of Biotech is the pod dedicated to leaders of emerging biopharma firms. SUBSCRIBE to our new newsletter at www.bioprocessonline.com/bob. We bring you insight into organizational, finance and funding, HR, clinical, manufacturing, regulatory, and commercial challenges you’ll face as you navigate your company from an idea to success in the clinic and beyond. Each episode features guest commentary and best practices from accomplished founders and biopharma industry luminaries. The Business of Biotech is produced by Life Science Connect.","last_synced_at":"2026-06-08T22:18:30.179389+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501"},"episode":{"title":"From Partnered ASO Therapies To A Wholly-Owned Pipeline With Ionis's Brett Monia, Ph.D.","slug":"from-partnered-aso-therapies-to-a-wholly-owned-pipeline-with-ionis-s-brett-monia-ph-d","published_at":"2026-05-04T10:00:00+00:00","page_url":"https://stenobird.com/podcast/business-of-biotech-123501/from-partnered-aso-therapies-to-a-wholly-owned-pipeline-with-ionis-s-brett-monia-ph-d","show_page_url":"https://stenobird.com/podcast/business-of-biotech-123501","url":"https://www.buzzsprout.com/1011661/episodes/19096332-from-partnered-aso-therapies-to-a-wholly-owned-pipeline-with-ionis-s-brett-monia-ph-d.mp3","audio_url":"https://www.buzzsprout.com/1011661/episodes/19096332-from-partnered-aso-therapies-to-a-wholly-owned-pipeline-with-ionis-s-brett-monia-ph-d.mp3","summary":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Brett Monia, Ph.D., CEO at Ionis Pharmaceuticals, talks about how antisense oligonucleotides (ASO) graduated from a late-1980s lab concept to real RNA-targeting medicines, and why Ionis stuck with a difficult modality despite multiple setbacks. Brett describes the company's shift from a partner-first model to building a wholly-owned pipeline, commercial function, and an expanded manufact...","meta_description":"We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, Brett Monia, Ph.D., CEO at Ionis Pharmaceuticals…","key_points":[],"chapters":[],"topics":[],"duration_seconds":3356,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/business-of-biotech-123501/episodes/from-partnered-aso-therapies-to-a-wholly-owned-pipeline-with-ionis-s-brett-monia-ph-d/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/business-of-biotech-123501/from-partnered-aso-therapies-to-a-wholly-owned-pipeline-with-ionis-s-brett-monia-ph-d.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}